Facebook
Twitter
LinkedIn
Forward2025 Department of Medicine Grand Rounds | Overview of Brain Parenchymal and Leptomeningeal Metastasis from Solid Malignancy
Consensus guidelines and expert opinions on managing brain metastasis and leptomeningeal diseases are rapidly evolving. However, interdisciplinary management on these complex cases continue to be lacking. This would also include research collaboration in terms of trials recruitment.
The gap exists because historically patients with CNS involvement have been excluded and were told to have poor prognosis. Now for the last decade, there are more systemic therapy and procedural interventions available to address these cases. Hence, clinicians can benefit from updated education about the current landscape of management to facilitate future collaboration. Clinician education and interdisciplinary discussion on management for each patient affected by the disease would increase the referrals to neuro-oncology division to facilitate the much needed inter-disciplinary management.
Target Audience
All physicians and other health care professionals interested in the subject matter.
Learning Objectives
- Outline the epidemiology of brain parenchymal metastasis.
- Discuss the main treatment methods for brain parenchymal metastasis.
- Identify common symptoms of and diagnostic methods for leptomeningeal disease from solid tumors.
- Examine the evidence behind the current treatment options for leptomeningeal disease from solid tumors.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Keng Lam, MD Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research, City of Hope
Presenter: Dr. Lam has indicated that there are no relevant financial relationships with ineligible companies.
Planner: Neal Prakash, MD has indicated that there are no relevant financial relationships with ineligible companies.
This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2025 Department of Medicine Grand Rounds | Overview of Brain Parenchymal and Leptomeningeal Metastasis from Solid Malignancy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance